Two T cells whose nutritional choices have changed their identity. On the left, a blue T cell prefers acetate and is active, able to continue fighting. On the right, a red T cell prefers citrate and ...

This image shows killer T cells surrounding and attacking a cancer cell. A new atlas developed by researchers at UC San Diego could make it possible to design custom T cells for immunotherapy to ...

A multi-institutional study led by researchers at UNC Lineberger Comprehensive Cancer Center, the Salk Institute for Biological Studies, and UC San Diego has uncovered new genetic rules that determine ...

By Hugo Francisco de Souza A novel CAR-T cell approach targets amyloid plaques in preclinical Alzheimer models, raising the ...

New findings reveal how cancer manipulates immune pathways and highlight therapeutic strategies to unleash T-cells against even the most resistant tumors. Study: Cancer cells impair monocyte-mediated ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

A substantial proportion of patients with autoimmune diseases experienced a new side effect called local immune effector cell–associated toxicity syndromes (LICATS) after receiving chimeric antigen ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...